Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gynecologic 4Other solid neoplasm 3

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
senaparib × Gynecologic × 1 year × Clear all
NCT07586449 2026-05-14

RESO

Zhejiang Cancer Hospital

Not yet recruiting
500 enrolled
Gynecologic

Ovarian Neoplasms

NCT04089189 2026-01-28

SABRINA

Impact Therapeutics, Inc.

Phase 2 Completed
93 enrolled
Gynecologic

Ovarian Neoplasms

NCT06617923 2025-10-27

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

Fudan University

Phase 2 Not yet recruiting
37 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡